scholarly journals Ovarian Cancer Treatment by Suicide Gene Therapy: Beauty of Nanotechnology in Medicine

2016 ◽  
Vol 3 (1) ◽  
Author(s):  
Abhimanyu Thakur
Keyword(s):  
Ovarian Cancer ◽  
Gene Therapy ◽  
Cancer Treatment ◽  
Suicide Gene ◽  
Suicide Gene Therapy

Nanoparticle‐Mediated Suicide Gene Therapy for Triple Negative Breast Cancer Treatment

2020 ◽  
Vol 3 (8) ◽  
pp. 2000007
Author(s):  
Lucia Salvioni ◽  
Stefania Zuppone ◽  
Francesco Andreata ◽  
Matteo Monieri ◽  
Serena Mazzucchelli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Therapy ◽  
Cancer Treatment ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Suicide Gene ◽  
Breast Cancer Treatment ◽  
Suicide Gene Therapy

Arf6-mediated macropinocytosis enhanced suicide gene therapy of C16TAB-condensed Tat/pDNA nanoparticles in ovarian cancer

Nanoscale ◽  
2021 ◽  
Author(s):  
Zhe Sun ◽  
Jinhai Huang ◽  
Linjia Su ◽  
Jing Li ◽  
Fangzheng Qi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Gene Therapy ◽  
Cancer Treatment ◽  
Plasmid Dna ◽  
Suicide Gene ◽  
Cell Penetrating Peptides ◽  
Therapeutic Gene ◽  
Hiv Tat ◽  
Efficient Delivery ◽  
Cell Penetrating

Using cell-penetrating peptides (CPPs), typically HIV-Tat, to deliver the therapeutic gene for cancer treatment has being hampered by low efficient delivery and complicated uptake route of plasmid DNA (pDNA). On...

Abstract 5928: Suicide gene therapy of ovarian cancer

2018 ◽  
Author(s):  
Obeid M. Malekshah ◽  
Siddik Sarkar ◽  
Arash Hatefi
Keyword(s):  
Ovarian Cancer ◽  
Gene Therapy ◽  
Suicide Gene ◽  
Suicide Gene Therapy

scholarly journals Molecular Basis of NDT-Mediated Activation of Nucleoside-Based Prodrugs and Application in Suicide Gene Therapy

Biomolecules ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 120
Author(s):  
Javier Acosta ◽  
Elena Pérez ◽  
Pedro A. Sánchez-Murcia ◽  
Cristina Fillat ◽  
Jesús Fernández-Lucas
Keyword(s):  
Gene Therapy ◽  
Cancer Treatment ◽  
Suicide Gene ◽  
Suicide Gene Therapy ◽  
Lactobacillus Delbrueckii ◽  
Clinical Implementation ◽  
Dynamics Simulations ◽  
Pronounced Reduction ◽  
Shed Light ◽  
Micromolar Range

Herein we report the first proof for the application of type II 2′-deoxyribosyltransferase from Lactobacillus delbrueckii (LdNDT) in suicide gene therapy for cancer treatment. To this end, we first confirm the hydrolytic ability of LdNDT over the nucleoside-based prodrugs 2′-deoxy-5-fluorouridine (dFUrd), 2′-deoxy-2-fluoroadenosine (dFAdo), and 2′-deoxy-6-methylpurine riboside (d6MetPRib). Such activity was significantly increased (up to 30-fold) in the presence of an acceptor nucleobase. To shed light on the strong nucleobase dependence for enzymatic activity, different molecular dynamics simulations were carried out. Finally, as a proof of concept, we tested the LdNDT/dFAdo system in human cervical cancer (HeLa) cells. Interestingly, LdNDT/dFAdo showed a pronounced reduction in cellular viability with inhibitory concentrations in the low micromolar range. These results open up future opportunities for the clinical implementation of nucleoside 2′-deoxyribosyltransferases (NDTs) in cancer treatment.

scholarly journals Adenoviral-Mediated Suicide Gene Therapy for Ovarian Cancer

2000 ◽  
Vol 2 (5) ◽  
pp. 524-530 ◽  
Author(s):  
Ronald D. Alvarez ◽  
Jesus Gomez-Navarro ◽  
Minghui Wang ◽  
Mack N. Barnes ◽  
Theresa V. Strong ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Gene Therapy ◽  
Suicide Gene ◽  
Suicide Gene Therapy

scholarly journals Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer

2002 ◽  
Vol 9 (5) ◽  
pp. 478-481 ◽  
Author(s):  
Dirk G Kieback ◽  
Dagmar-Christiane Fischer ◽  
Dirk G Engehausen ◽  
Willi Sauerbrei ◽  
Martin K Oehler ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Gene Therapy ◽  
Nude Mice ◽  
Suicide Gene ◽  
Suicide Gene Therapy ◽  
Human Ovarian Cancer

scholarly journals Development of iRGD-Modified Peptide Carriers for Suicide Gene Therapy of Uterine Leiomyoma

Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 202
Author(s):  
Anna Egorova ◽  
Sofia Shtykalova ◽  
Alexander Selutin ◽  
Natalia Shved ◽  
Marianna Maretina ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Uterine Leiomyoma ◽  
Transfection Efficiency ◽  
Chemical Properties ◽  
Suicide Gene ◽  
Suicide Gene Therapy ◽  
Benign Tumors ◽  
Αvβ3 Integrin ◽  
Peptide Carrier ◽  
Plasmid Delivery

Uterine leiomyoma (UL) is one of the most common benign tumors in women that often leads to many reproductive complications. Suicide genetherapy was suggested as a promising approach for UL treatment. In the present study, we describe iRGD ligand-conjugated cysteine-rich peptide carrier RGD1-R6 for targeted DNA delivery to αvβ3 integrin-expressing primary UL cells. The physico-chemical properties, cytotoxicity, transfection efficiency and specificity of DNA/RGD1-R6 polyplexes were investigated. TheHSV-1thymidine kinase encoding plasmid delivery to PANC-1pancreatic carcinoma cells and primary UL cells resulted in significant suicide gene therapy effects. Subsequent ganciclovir treatment decreased cells proliferative activity, induced of apoptosis and promoted cells death.The obtained results allow us to concludethatthe developed RGD1-R6 carrier can be considered a promising candidate for suicide gene therapy of uterine leiomyoma.

Sign in / Sign up

Export Citation Format

Share Document